NASDAQ:BGMS Cyclacel Pharmaceuticals (BGMS) Stock Price, News & Analysis $0.88 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.87 -0.01 (-1.36%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsSEC Filings About Cyclacel Pharmaceuticals Stock (NASDAQ:BGMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BGMS alerts:Sign Up Key Stats Today's Range$0.88▼$0.9150-Day Range$0.83▼$1.0552-Week Range$0.57▼$6.70Volume9,808 shsAverage Volume175,149 shsMarket Capitalization$4.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted medicines for the treatment of cancer. The company’s research programs are designed to address molecular pathways involved in tumor growth and survival, with an emphasis on therapies for patients with limited treatment options. Cyclacel’s pipeline has included fadraciclib, an oral cyclin-dependent kinase inhibitor designed to target CDK2 and CDK9, and sapacitabine, an oral nucleoside analogue investigated for certain hematologic malignancies and solid tumors. The company has also pursued additional oncology programs involving cell-cycle regulation and other cancer-related targets. Cyclacel was founded in the United Kingdom and has conducted research and clinical development activities internationally. The company has been led by Chief Executive Officer Spiro Rombotis. Cyclacel Pharmaceuticals has historically traded under the Nasdaq symbol CYCC; the symbol provided, BGMS, could not be independently verified as the company’s current trading symbol.AI Generated. May Contain Errors. Read More Cyclacel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreBGMS MarketRank™: Cyclacel Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCyclacel Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCyclacel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cyclacel Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.16% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.27, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently increased by 160.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.28 News SentimentCyclacel Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders23.75% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.Read more about Cyclacel Pharmaceuticals' insider trading history. Receive BGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BGMS Stock News HeadlinesBoise Cascade (NYSE:BCC) vs. Cyclacel Pharmaceuticals (NASDAQ:BGMS) Head to Head SurveyOctober 1, 2026 | americanbankingnews.com$HAREHOLDER ALERT - The M&A Class Action Firm Continues to Investigate the Merger— ATKR, BZH, BGMS and CBANSeptember 30, 2026 | globenewswire.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.October 5 at 1:00 AM | Paradigm Press (Ad)Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Sees Large Growth in Short InterestSeptember 27, 2026 | americanbankingnews.comEQUITY ALERT: The M&A Class Action Firm Launches Inquiry for the Merger— ATKR, BGMS, BOW and FTHMSeptember 8, 2026 | globenewswire.comBIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEAugust 12, 2026 | globenewswire.comBio Green Med Solution Surges 172% After Announcing Deal to Acquire Malaysia Waste Tech CompanyJune 5, 2026 | benzinga.comBGMS Stock Alert: Halper Sadeh LLC is Investigating Whether Bio Green Med Solution, Inc. is Obtaining a Fair Price for its ShareholdersJune 4, 2026 | businesswire.comSee More Headlines BGMS Stock Analysis - Frequently Asked Questions How have BGMS shares performed this year? Cyclacel Pharmaceuticals' stock was trading at $1.48 on January 1st, 2026. Since then, BGMS shares have decreased by 40.5% and is now trading at $0.88. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) posted its quarterly earnings results on Friday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $0.34 million for the quarter. Cyclacel Pharmaceuticals had a negative trailing twelve-month return on equity of 31.60% and a negative net margin of 118.27%. How do I buy shares of Cyclacel Pharmaceuticals? Shares of BGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today10/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BGMS's financial health is in the Green zone, according to TradeSmith. BGMS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Trading Companies & Distributors Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:BGMS CIK1130166 Webwww.bgmsglobal.com Phone(908) 517-7330Fax866-271-3466Employees12Year Founded1996Profitability EPS (Trailing Twelve Months)($3.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3 million Net Margins-118.27% Pretax Margin102.10% Return on Equity-31.60% Return on Assets-27.72% Debt Debt-to-Equity RatioN/A Current Ratio8.63 Quick Ratio7.22 Sales & Book Value Annual Sales$750 thousand Price / Sales6.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book0.63Miscellaneous Outstanding Shares5,520,000Free Float4,208,000Market Cap$4.86 million OptionableN/A Beta-0.39 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BGMS) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
